PDGFRA and glioblastoma: Where assessable in the same sample, we observed amplification of all three genes in 24/154 (15.6%) glioblastoma cases (24/41, 58.5% of 4q12-amplified cases), PDGFRA and KIT in 8/154 (5.2%) (8/41, 19.5% 4q12-amplified) and PDGFRA only in 9/154 (5.8%) (9/41, 21.9% 4q12-amplified), (Figure 3A).